Medical Devices

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

Germany's startups attracted €1.7B in Q1 2026, fueled by US investors and a massive bet on artificial intelligence, signaling a new era for its ecosystem.

This Vision Health Month, learn why your eyes need more than a simple check-up and how a surgeon's specialized medical expertise is key to preventing vision loss.

A new 'dream team' of experts will guide AI development to create non-invasive tools for a deadly lung disease, aiming to replace painful procedures.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

The new Spring 2026 platform moves beyond data storage, using AI to transform MedTech regulatory affairs into a strategic, high-speed execution engine.

neurocare's TMS device approval marks a major shift in the Kingdom's approach to depression, prioritizing non-invasive, tech-driven solutions.

A top European fertility network is rolling out AI to select embryos, promising higher success rates but sparking debate on the future of data-driven parenthood.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

A novel medical food for IBS shows remarkable efficacy in new studies, exceeding FDA benchmarks for pain relief and solving the long-standing issue of taste.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

A new intraoperative MRI gives surgeons real-time vision, promising more precise and safer glioma removal as it moves toward the competitive U.S. market.

Leixir Dental Group is launching two specialized labs, betting on advanced tech and artistry to dominate the lucrative full-arch and cosmetic dentistry markets.

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

A strategic acquisition brings a top impairment expert's training under a leading online platform, set to redefine workers' compensation professional development.

A landmark partnership between Propella Group and TISTR aims to unlock Thailand's hidden scientific gems, creating a pipeline for global VCs.

With its Juveena hydrogel pending FDA approval, Rejoni brings in a commercialization expert to tackle the underserved market for intrauterine adhesions.